Balancing Soaring Costs and Employee Well-being in Weight Loss Drug Coverage
In this article, you'll get:
Employer-Sponsored Health Plans: A Mixed Coverage Landscape
Even though the weight-loss drugs such as Wegovy have been approved by FDA for chronic weight management, it doesn’t guarantee your health insurance plan will cover them. Recent data highlights a complex scenario in the coverage of weight-loss medications within employer-sponsored health plans. An October 2023 survey by the International Foundation of Employee Benefit Plans involving 205 companies found a significant disparity: while 76% of these plans cover GLP-1 drugs for diabetes, only 27% extend this coverage to weight loss. Additionally, 13% of plan sponsors are contemplating adding coverage for weight-loss purposes.
The relatively low rate of coverage for weight-loss medications in employer-sponsored health plans is primarily due to the significant financial burden these drugs can impose. GLP-1 medications, such as Ozempic and Wegovy, are not only highly effective but also notably expensive, often costing over $1,000 per month. This high cost can significantly impact the overall spending of health plans, prompting employers and insurers to carefully consider the long-term financial implications of including such drugs in their coverage. As a result, many plans opt to limit coverage to specific medical conditions like diabetes where these medications have demonstrated considerable benefits in terms of cost-effectiveness and overall health outcomes.
Self-insured vs. Fully-Insured Plans—Regulated Differently but No Mandate for Weight Loss Drug Coverage
Most Americans with employer-sponsored health insurance are covered under self-insured plans, where the employer itself assumes the financial risk of medical costs rather than purchasing a traditional insurance policy. These plans are regulated under the Employee Retirement Income Security Act (ERISA) and are not subject to state insurance laws, allowing for more flexibility in plan design. This means that coverage of weight-loss drugs can significantly vary, as it depends on the employer’s specific health benefit design choices.
In contrast, fully-insured commercial health plans involve a traditional insurance arrangement where the insurance company assumes the financial risk. Employers in this setup pay a fixed premium to the insurance company, which then pays for the employees' medical claims. These plans are more common in larger-size companies (or in insurance company’s term, the large-group market), , but they also apply to the small-group market, which is defined as employers with 50 or fewer employees. In this small-group market, plans must conform to the state's Essential Health Benefits (EHB) benchmark plan, which typically does not include coverage for weight-loss drugs. This regulatory requirement directly impacts the coverage options available for weight-loss medications within these health plans.
Many Employers Restrict the Coverage, While Others Embrace It
Given the financial challenges posed by GLP-1 drugs, some companies are imposing significant restrictions or cutting coverage altogether due to cost concerns. For instance, the Mayo Clinic implemented a lifetime cap of $20,000 on spending for these drugs starting January 1st as part of their employee medical benefits, reflecting a targeted approach to manage costs while still providing some level of coverage.
Separately, North Carolina’s health plan for state employees recently made a more drastic change by deciding to eliminate reimbursement for GLP-1s used for weight loss starting in April. This decision was driven by projected cost increases, with estimates suggesting that the cost could grow to more than $1 billion by 2030, potentially doubling the amount that enrolled members would have to pay in monthly premiums for their coverage.
The picture is not universally bleak. A survey by Accolade reveals that 99% of employers who cover GLP-1 medications plan to continue. These employers, though representing only 25% of respondents, report benefits like enhanced employee satisfaction and improved health conditions. This contrast highlights the diverse approaches to managing the financial impacts of weight loss drug coverage.
Marketplace Plans and GLP-1 Coverage: Varies by State with Policy Shifts on the Horizon
Marketplace plans, also known as Affordable Care Act (ACA) plans, are health insurance options available through state or federal exchanges, designed to provide accessible, affordable healthcare with essential benefits.
Under the Affordable Care Act (ACA), individual and small-group plans must cover at least one drug in every category and class defined by the United States Pharmacopeia (USP). However, as of now, weight-loss drugs are not required under these rules, leaving coverage decisions largely to individual states. While most states have not updated their EHB benchmark plans since 2017, only a handful like New Mexico have recently included weight-loss medications, reflecting a shift towards recognizing the medical necessity of treating obesity.
The landscape might evolve soon, as the Department of Health and Human Services (HHS) considered public comments in 2023 about potentially changing formulary coverage rules to include weight-loss drugs. Though no changes were made in the final rule of April 2024, the dialogue suggests a growing awareness and potential for more inclusive coverage in future updates.
Cost-Saving Strategies for Consumers
In the meantime, consumers facing non-coverage or high costs have several strategies to consider. Firstly, understanding the specifics of employer-provided benefits is crucial, as some plans might cover these drugs under certain conditions, like meeting a BMI threshold or participating in wellness programs. For those with commercial insurance, exploring manufacturer savings programs can provide significant relief (my cost article). Websites for drugs like Wegovy and Zepbound often offer discount programs, although eligibility criteria can be stringent.
Additionally, while looking abroad for cheaper medications might seem like an option, current research and shortages make this less viable for weight-loss drugs (pipeline article link). The focus on high prices, like those investigated by Sen. Bernie Sanders, highlights the broader issue of pharmaceutical pricing and its impact on accessibility and affordability (pricing probe article).
Final Thoughts: Reducing Drug Prices is Key to Affordable Coverage
As the healthcare landscape continues to adapt, both employer-sponsored and marketplace health plans face a dynamic yet challenging environment for covering weight-loss medications. The ongoing policy discussions and consumer strategies reveal a complex interplay of regulatory frameworks, economic considerations, and individual health needs. Crucially, reducing drug prices by pharmaceutical companies will play a fundamental role in keeping costs down and enabling broader coverage. Moving forward, understanding these nuances will be key for consumers, business stakeholders, and policymakers alike in managing and potentially expanding coverage for these essential treatments.
Reference: